Fig. 1: Group-average tau-PET levels.
From: Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease
Group-average tau-PET levels for the ADNI (a–c) and BioFINDER (d–e) samples, stratified by diagnostic group. Tau-PET levels are showed as continuous values, where pathological tau-PET levels (i.e., surpassing an SUVR of 1.3)26 are highlighted by white outlines in Panels a–g. Group-average data are shown in ADNI for 28 CN Aβ− (a), 32 CN Aβ+ (b) and 21 MCI Aβ+ (c) at baseline and follow-up. For BioFINDER, group-average data are shown for 16 CN Aβ− (d), 16 CN Aβ+ (e), 7 MCI Aβ+ (f) and 18 AD Dementia patients (g). In ADNI, ROI-wise t-tests against zero show no significant annual tau-PET increases in 28 CN Aβ− (h), but significant (p < 0.005) temporo-parietal tau-PET changes in 53 Aβ+ (i). In BioFINDER, t-tests against zero show minor annual tau-PET increases in the 16 CN Aβ− (j), but widespread temporal, parietal and frontal tau-PET increases in the 41 Aβ+ subjects (k).
